Go Pro
→ Trump's new AI tirade hurting GOP? (From Stansberry Research) (Ad)tc pixel Free TIL Stock Alerts

Instil Bio (TIL) Competitors

Instil Bio logo
$7.09 -0.12 (-1.66%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$7.11 +0.02 (+0.28%)
As of 09/18/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

TIL vs. ABOS, TNXP, VYGR, PRQR, and ORMP

Should you buy Instil Bio stock or one of its competitors? Instil Bio's main competitors and comparable companies include Acumen Pharmaceuticals (ABOS), Tonix Pharmaceuticals (TNXP), Voyager Therapeutics (VYGR), ProQR Therapeutics (PRQR), and Oramed Pharmaceuticals (ORMP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Instil Bio compare to Acumen Pharmaceuticals?

Instil Bio (NASDAQ:TIL) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Instil Bio has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market.

Instil Bio currently has a consensus price target of $7.00, indicating a potential downside of 1.27%. Acumen Pharmaceuticals has a consensus price target of $7.00, indicating a potential upside of 164.15%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Instil Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Instil Bio
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Acumen Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

In the previous week, Acumen Pharmaceuticals had 8 more articles in the media than Instil Bio. MarketBeat recorded 8 mentions for Acumen Pharmaceuticals and 0 mentions for Instil Bio. Acumen Pharmaceuticals' average media sentiment score of 0.56 beat Instil Bio's score of 0.00 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Instil Bio Neutral
Acumen Pharmaceuticals Positive

Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Instil BioN/AN/A-$71.37M-$4.47N/A
Acumen PharmaceuticalsN/AN/A-$121.33M-$1.63N/A

60.6% of Instil Bio shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 47.0% of Instil Bio shares are held by company insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Instil Bio's return on equity of -26.78% beat Acumen Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Instil BioN/A -26.78% -14.89%
Acumen Pharmaceuticals N/A -136.27%-81.64%

Summary

Acumen Pharmaceuticals beats Instil Bio on 7 of the 13 factors compared between the two stocks.

How does Instil Bio compare to Tonix Pharmaceuticals?

Instil Bio (NASDAQ:TIL) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Instil Bio has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -548.64%. Instil Bio's return on equity of -26.78% beat Tonix Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Instil BioN/A -26.78% -14.89%
Tonix Pharmaceuticals -548.64%-68.99%-61.31%

Instil Bio currently has a consensus target price of $7.00, indicating a potential downside of 1.27%. Tonix Pharmaceuticals has a consensus target price of $24.50, indicating a potential upside of 125.39%. Given Tonix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Tonix Pharmaceuticals is more favorable than Instil Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Instil Bio
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Tonix Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
2 Strong Buy rating(s)
3.00

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Instil Bio has higher earnings, but lower revenue than Tonix Pharmaceuticals. Instil Bio is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Instil BioN/AN/A-$71.37M-$4.47N/A
Tonix Pharmaceuticals$13.11M14.22-$124.02M-$12.94N/A

In the previous week, Tonix Pharmaceuticals had 2 more articles in the media than Instil Bio. MarketBeat recorded 2 mentions for Tonix Pharmaceuticals and 0 mentions for Instil Bio. Tonix Pharmaceuticals' average media sentiment score of 0.39 beat Instil Bio's score of 0.00 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Instil Bio Neutral
Tonix Pharmaceuticals Neutral

Instil Bio has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market.

Summary

Tonix Pharmaceuticals beats Instil Bio on 8 of the 15 factors compared between the two stocks.

How does Instil Bio compare to Voyager Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and Instil Bio (NASDAQ:TIL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

Instil Bio has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -312.63%. Instil Bio's return on equity of -26.78% beat Voyager Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Voyager Therapeutics-312.63% -57.92% -45.00%
Instil Bio N/A -26.78%-14.89%

Instil Bio has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Voyager Therapeutics$40.37M4.72-$119.72M-$1.80N/A
Instil BioN/AN/A-$71.37M-$4.47N/A

In the previous week, Voyager Therapeutics' average media sentiment score of 0.00 equaled Instil Bio'saverage media sentiment score.

Company Overall Sentiment
Voyager Therapeutics Neutral
Instil Bio Neutral

Voyager Therapeutics has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Instil Bio has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market.

Voyager Therapeutics currently has a consensus price target of $16.50, suggesting a potential upside of 433.98%. Instil Bio has a consensus price target of $7.00, suggesting a potential downside of 1.27%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Voyager Therapeutics is more favorable than Instil Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Voyager Therapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75
Instil Bio
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 60.6% of Instil Bio shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by insiders. Comparatively, 47.0% of Instil Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Instil Bio beats Voyager Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Instil Bio compare to ProQR Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and Instil Bio (NASDAQ:TIL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 60.6% of Instil Bio shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by company insiders. Comparatively, 47.0% of Instil Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Instil Bio has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -223.51%. Instil Bio's return on equity of -26.78% beat ProQR Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ProQR Therapeutics-223.51% -73.83% -35.14%
Instil Bio N/A -26.78%-14.89%

ProQR Therapeutics presently has a consensus target price of $7.50, indicating a potential upside of 309.84%. Instil Bio has a consensus target price of $7.00, indicating a potential downside of 1.27%. Given ProQR Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe ProQR Therapeutics is more favorable than Instil Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ProQR Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
Instil Bio
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

ProQR Therapeutics has higher revenue and earnings than Instil Bio. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProQR Therapeutics$17.99M10.72-$47.73M-$0.46N/A
Instil BioN/AN/A-$71.37M-$4.47N/A

ProQR Therapeutics has a beta of 0.06, indicating that its stock price is 94% less volatile than the broader market. Comparatively, Instil Bio has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market.

In the previous week, ProQR Therapeutics' average media sentiment score of 0.00 equaled Instil Bio'saverage media sentiment score.

Company Overall Sentiment
ProQR Therapeutics Neutral
Instil Bio Neutral

Summary

Instil Bio beats ProQR Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Instil Bio compare to Oramed Pharmaceuticals?

Instil Bio (NASDAQ:TIL) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Instil Bio currently has a consensus price target of $7.00, indicating a potential downside of 1.27%. Given Instil Bio's higher probable upside, equities analysts plainly believe Instil Bio is more favorable than Oramed Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Instil Bio
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Oramed Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

60.6% of Instil Bio shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 47.0% of Instil Bio shares are held by insiders. Comparatively, 20.8% of Oramed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Oramed Pharmaceuticals' return on equity of -5.17% beat Instil Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Instil BioN/A -26.78% -14.89%
Oramed Pharmaceuticals N/A -5.17%-4.54%

Instil Bio has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market.

Oramed Pharmaceuticals has higher revenue and earnings than Instil Bio. Instil Bio is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Instil BioN/AN/A-$71.37M-$4.47N/A
Oramed Pharmaceuticals$2M98.59$64.05M$4.121.15

In the previous week, Oramed Pharmaceuticals had 1 more articles in the media than Instil Bio. MarketBeat recorded 1 mentions for Oramed Pharmaceuticals and 0 mentions for Instil Bio. Oramed Pharmaceuticals' average media sentiment score of 0.55 beat Instil Bio's score of 0.00 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Instil Bio Neutral
Oramed Pharmaceuticals Positive

Summary

Oramed Pharmaceuticals beats Instil Bio on 9 of the 13 factors compared between the two stocks.

Get Instil Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for TIL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TIL vs. The Competition

Export
MetricInstil BioBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$48.08M$3.88B$7.24B$12.95B
Dividend YieldN/A3.64%2.57%12.80%
P/E Ratio-1.5914.23275.4925.40
Price / SalesN/A1,423.44639.5587.39
Price / CashN/A108.9076.2551.42
Price / Book0.4215.4510.466.33
Net Income-$71.37M-$22.86M$3.49B$358.33M
7 Day Performance-3.93%-1.21%0.59%1.12%
1 Month Performance-4.58%-3.29%-1.74%-2.39%
1 Year Performance-64.43%37.74%18.13%5.35%

Instil Bio Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TIL
Instil Bio
0.6898 of 5 stars		$7.09
-1.7%		$7.00
-1.3%		-64.4%$48.08MN/AN/A410
ABOS
Acumen Pharmaceuticals
2.9434 of 5 stars		$2.89
+3.6%		$7.00
+142.2%		+110.3%$201.76MN/AN/A61
TNXP
Tonix Pharmaceuticals
4.1397 of 5 stars		$11.62
-0.9%		$24.50
+110.8%		-58.2%$201.18M$29.10MN/A142
VYGR
Voyager Therapeutics
2.606 of 5 stars		$3.09
-3.1%		$16.50
+434.0%		-27.6%$196.56M$40.37MN/A141
PRQR
ProQR Therapeutics
3.3995 of 5 stars		$1.84
-1.1%		$7.50
+307.6%		-12.9%$195.97M$17.99MN/A166

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TIL) was last updated on 9/20/2026 by MarketBeat.com Staff.
From Our Partners
$40,000,000,000,000
The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...
American Alternative | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Gold did this exact thing in 1975… [then exploded]
In 1975 the Fed raised rates and gold fell 50 percent. Headlines called the gold bull market dead. Instead gol...
Golden Portfolio | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Why I went to Mount Rushmore
A small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...
Stansberry Research | Sponsoredtc pixel
What Elon Musk did in June 2024
In June 2024, Elon Musk faced a problem every AI company was about to hit — how to power a massive AI computer...
Behind the Markets | Sponsoredtc pixel
The Last Gold Bull Market?
Former CIA and Pentagon official Jim Rickards says the current gold bull market could be its last. Investment ...
Paradigm Press | Sponsoredtc pixel